<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02470871</url>
  </required_header>
  <id_info>
    <org_study_id>CSL689_1002</org_study_id>
    <secondary_id>2014-002982-32</secondary_id>
    <nct_id>NCT02470871</nct_id>
  </id_info>
  <brief_title>Study of the Pharmacokinetics and Safety of Recombinant Factor VIIa Fusion Protein (rVIIa-FP, CSL689) in Patients With Congenital Factor VII Deficiency</brief_title>
  <official_title>Multi-center, Randomized, Open-label, Parallel-Arm, Single-dose, Pharmacokinetic Study of rVIIa-FP (CSL689) in Subjects With Congenital Factor VII Deficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CSL Behring</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CSL Behring</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the pharmacokinetics (PK) and safety of rVIIa-FP&#xD;
      (CSL689) in a total of 10 to 16 male or female adults with inherited coagulation factor VII&#xD;
      (FVII) deficiency. Subjects will receive a single dose of their routine FVII replacement&#xD;
      product (ie, either recombinant activated coagulation FVII [rFVIIa, eptacog alfa (activated)]&#xD;
      or plasma-derived FVII [pdFVII]) as a comparator, and will then be randomly assigned to a&#xD;
      single low dose or a single high dose of the study product CSL689 (8 subjects per CSL689 dose&#xD;
      level). Serial blood samples for PK analysis will be taken up to 24 hours after the eptacog&#xD;
      alfa (activated) or pdFVII injection, and up to 48 hours after the CSL689 injection. Subject&#xD;
      safety will be routinely monitored throughout the study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Terminal half-life of plasma FVIIa activity</measure>
    <time_frame>Up to 48 hours after CSL689 injection</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed plasma FVIIa activity</measure>
    <time_frame>Before injection and at up to 9 time points until 48 hours after injection</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the curve (AUC0-t)</measure>
    <time_frame>Before injection and at up to 9 time points until 48 hours after injection</time_frame>
    <description>Area under plasma FVIIa activity versus time curve from time 0 to last sample with quantifiable activity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total clearance</measure>
    <time_frame>Before injection and at up to 9 time points until 48 hours after injection</time_frame>
    <description>Total clearance of plasma FVIIa activity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution of the terminal phase</measure>
    <time_frame>Before injection and at up to 9 time points until 48 hours after injection</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-inf)</measure>
    <time_frame>Before injection and at up to 9 time points until 48 hours after injection</time_frame>
    <description>Area under plasma FVIIa activity versus time curve from time 0 extrapolated to infinity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incremental recovery</measure>
    <time_frame>Before injection and at up to 9 time points until 48 hours after injection</time_frame>
    <description>Incremental recovery of plasma FVIIa activity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of occurrence of maximum observed plasma FVIIa activity</measure>
    <time_frame>Before injection and at up to 9 time points until 48 hours after injection</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with antibodies against Chinese hamster ovary protein and FVII</measure>
    <time_frame>Up to 30 days after CSL689 injection</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with inhibitors against FVII</measure>
    <time_frame>Up to 30 days after CSL689 injection</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Congenital Coagulation Factor VII Deficiency</condition>
  <arm_group>
    <arm_group_label>Low-dose CSL689</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of subject's routine FVII replacement therapy (either eptacog alfa [activated] [ie, comparator drug 1] or pdFVII [ie, comparator drug 2]), followed by a single dose of CSL689 at the low dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High-dose CSL689</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of subject's routine FVII replacement therapy (either eptacog alfa [activated] [ie, comparator drug 1] or pdFVII [ie, comparator drug 2]), followed by a single dose of CSL689 at the high dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Eptacog alfa (activated) or pdFVII</intervention_name>
    <description>Comparator Drug 1: Recombinant activated FVII (rFVIIa). Subjects with eptacog alfa (activated) as their routine FVII replacement therapy will receive a single dose of eptacog alfa (activated) in the study.&#xD;
Comparator Drug 2: Plasma-derived FVII (pdFVII). Subjects with pdFVII as their routine FVII replacement therapy will receive a single injection of pdFVII in the study.</description>
    <arm_group_label>High-dose CSL689</arm_group_label>
    <arm_group_label>Low-dose CSL689</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CSL689</intervention_name>
    <description>Experimental Drug: Recombinant fusion protein, linking activated FVII with albumin (rVIIa-FP). Subjects will receive a single dose of CSL689 at either a low dose (Arm 1) or a high dose (Arm 2)</description>
    <arm_group_label>High-dose CSL689</arm_group_label>
    <arm_group_label>Low-dose CSL689</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Proven congenital FVII deficiency.&#xD;
&#xD;
          -  Age ≥ 18 years.&#xD;
&#xD;
          -  FVII level &lt; 2% of normal levels.&#xD;
&#xD;
          -  Minimum of 50 previous exposure days to pdFVII (including prothrombin complex&#xD;
             concentrates [PCCs]) or rFVIIa.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of, or risk factors for, thromboembolic events, including known deep vein&#xD;
             thrombosis.&#xD;
&#xD;
          -  Inhibitor to FVII or rFVIIa, current or historic.&#xD;
&#xD;
          -  Known or suspected hypersensitivity to hamster protein, to CSL689, or to any excipient&#xD;
             of CSL689.&#xD;
&#xD;
          -  Known or suspected allergy to rFVIIa or hamster protein.&#xD;
&#xD;
          -  Major surgery within 1 month before screening.&#xD;
&#xD;
          -  Advanced atherosclerotic disease (ie, known history of ischemic heart disease, or&#xD;
             ischemic stroke).&#xD;
&#xD;
          -  Human immunodeficiency virus (HIV)-positive subjects with cluster of differentiation 4&#xD;
             (CD4)+ lymphocyte count of &lt; 200/µL at screening.&#xD;
&#xD;
          -  Use of an investigational agent within 30 days before the study.&#xD;
&#xD;
          -  Use of concomitant therapy not permitted during the study (ie, other platelet&#xD;
             inhibitors, desmopressin, fibrinolysis inhibitors, except if used as local treatment&#xD;
             [eg, for oral bleeds])&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alex Veldman</last_name>
    <role>Study Director</role>
    <affiliation>CSL Behring</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site Reference 5280023</name>
      <address>
        <city>Njmegen</city>
        <zip>6500</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference # 5780001</name>
      <address>
        <city>Oslo</city>
        <zip>0372</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
    <country>Norway</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <study_first_submitted>June 10, 2015</study_first_submitted>
  <study_first_submitted_qc>June 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 12, 2015</study_first_posted>
  <last_update_submitted>April 25, 2017</last_update_submitted>
  <last_update_submitted_qc>April 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Factor VII Deficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

